Work

Analyse der IL-17R-, IL-22R- und GM-CSFR-Oberflächenexpression auf CD19+ und CD19- Plasmablasten und deren Bedeutung bei Patienten mit rheumatoider Arthritis

Year: 2023
Type: dissertation
Study design: Observational Study
Abstract: Background and goals Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that clinically presents as polyarthritis but can manifest as a systemic disease in numerous organs. Early phases of the disease are characterized by loss of immunological tolerance and the presence of autoantibodies. Clinical onset of the disease may be preceded by a period of autoantibody positivity lasting up to ten years with concomitant absence of symptoms. Previous work has shown that autoantibodies specific for RA have altered glycan structures in their Fc fragments. By decreasing terminal sialylation, these autoantibodies can no longer bind anti-inflammatory receptors and thus induce primarily pro-inflammatory processes. Progression of these autoreactive processes results in chronic synovitis, which can eventually lead to destruction of articular cartilage and bone. The IL-23/TH17 axis exerts a key role in the etiopathogenesis of rheumatoid arthritis. The work of Pfeifle et al. (2017) has shown that IL-23 activated TH17-cells can suppress the expression of st6gal1 and thus the activity of alpha2,6-sialyltransferase in plasmablasts in vivo and thus influence the glycan structure of the autoantibodies. Decreasing sialylation of autoantibodies increases their inflammatory potential. However, it is still unclear how exactly the TH17-mediated signals are transmitted to B cells and plasmablasts and what significance this has for disease development and maintenance. To this end, in this work, the surface expression of cytokine receptors for IL-17, IL-22, and GM-CSF on CD19+CD27+CD38+- and CD19-CD27+CD38+-peripheral blood plasmablasts from 20 clinically active ACPA+ RA patients was compared with those from 20 healthy volunteers. These cytokines are under the influence of the IL-23/TH17 axis and may be responsible for the necessary signal transduction between TH-17 cell and B cell. Increased expression of these cytokine receptors in diseased individuals may provide additional insight into the etiopathogenesis of this disease. Methods To investigate receptor expression on human plasmablasts, whole blood was obtained from 20 diseased patients with detectable ACPA autoantibodies from the RA cohort of the Medical Clinic 3 of the University Hospital Erlangen and compared with that of 20 healthy subjects. Furthermore, the disease activity was determined in the context of the medical history and physical examination. Receptor expression was determined by flow cytometry after prior cell isolation and antibody labeling. Software-based analysis and interpretation of the raw data followed the laboratory-based analysis. Results GM-CSFR was shown to be significantly more expressed on CD19+CD27+CD38+- and CD19-CD27+CD38+-plasmablasts in the RA cohort compared with the control group. No significant differences were detected for IL-17R and IL-22R between the control group and patients. Discussion The increased expression of GM-CSFR on the examined plasmablasts of diseased individuals suggests that GM-CSF, via its intracellular signaling cascades, is a cytokine potentially responsible for the pathogenic properties of B cells and plasmablasts in RA patients. This might involve the decreased st6gal1 expression in RA plasmablasts. Although IL-17R and IL-22R do not show significant differences in surface expression, they may still be involved in the maintenance of inflammatory processes. However, further studies both in vivo and in vitro are necessary for the deeper understanding of the etiopathogenesis, especially to investigate the intracellular signaling cascades and expression mechanisms triggered by GM-CSF from the st6gal1 gene. In addition, testing of the correlation of receptor expression with routinely collected laboratory parameters or disease activity may also be performed to provide clinical context. On the long run, diagnostic or therapeutic consequences would be desirable to block the pathogenic B cell response and to intervene before the onset of Inflammation in a preventive manner. Targeting cytokines such as GM-CSF might thus impose an attractive therapeutic target to beneficially influence the course of this disease in order to prevent irreversible joint destruction.
Author: Alexander Weber
Language: German
Subfield: Rheumatology
Field: Medicine
Open Access status: green
OpenAlex ID: W7054570117
Cites: 103
Cited by:
Related to: 10